Company intelligence / Profile preview

Stimvia

Ownership: Private
Development stage: Commercial

Overview

Stimvia’s URIS® device has demonstrated significant symptom relief (>90% of patients) in overactive bladder with a strong safety profile and no serious adverse events. Pilot studies for Parkinson's disease show promising improvements in symptoms and quality of life; full data pending as of mid 2025.

Therapeutic areas: NeurologyUrology
Modalities: DeviceNon-pharmacological therapyNeuromodulation
Industry: Therapeutic Medical Devices

Partnerships

Participated in NYU Stern Endless Frontier Labs accelerator program

Beyond the preview

Go deeper on Stimvia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stimvia.

Explore the full profile